Clinical trials: Advanced Solid Tumors
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
HV-101 for Patients With Advanced Solid Tumors
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients.
- Trial name
- NCT05868915
- Testing
- HV-101
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Hervor Therapeutics
Advanced Solid Tumor
TIL for Patients With Advanced Solid Tumor
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to patients.
- Trial name
- NCT06334783
- Testing
- Autologous tumor-infiltrating lymphocyte cells
- Where
- 3 sites in China
- Volunteers
- 5 people
- Sponsor
- Hervor Therapeutics
Advanced and Relapsed Solid Tumors
Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors
In this study, microtransplantation (MST) will be administrated to patients diagnosed with advanced / relapsed solid tumors to assess the therapeutic efficacy and safety of conventional chemotherapy in combination with MST for…
- Trial name
- NCT07356856
- Testing
- MST
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Patients With Any Advanced Solid Tumors
Trial Of Pembrolizumab And Nintedanib
Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable.
- Trial name
- PEMBIB (NCT02856425)
- Testing
- Nintedanib, Pembrolizumab
- Where
- 5 sites in France
- Volunteers
- 196 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced Solid Tumors
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Alkaline phosphatase (ALP) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphates at alkaline pH values. As one of the earliest discovered oncofetal antigens, ALP has emerged as a significant biomarker for…
- Trial name
- NCT06556108
- Testing
- ALPP CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xinqiao Hospital of Chongqing
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Tumor
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults…
- Trial name
- POLAR (NCT06560632)
- Testing
- RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumors
A Study of HS-20122 in Patients With Advanced Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced…
- Trial name
- NCT06927570
- Testing
- HS-20122
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumors
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.
- Trial name
- NCT07186452
- Testing
- HS-20093, Itraconazole
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Solid Tumors
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical…
- Trial name
- NCT07231458
- Testing
- ABX-001, Pembrolizumab
- Where
- 5 sites in Germany, Spain
- Volunteers
- 27 people
- Sponsor
- Abalos Therapeutics GmbH
Advanced Solid Tumors
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
- Trial name
- NCT07349160
- Testing
- Metabolically Armed TIL cells.
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumor
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.
- Trial name
- NCT05163041
- Testing
- BT7480, Nivolumab
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- BicycleTx Limited
Advanced Solid Tumor
A Clinical Study of ZL-85FA Tablets
An open-label, multicenter phase I/IIa clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZL-85FA tablets in treating advanced solid tumors
- Trial name
- NCT07339748
- Testing
- ZL-85FA tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Advanced Solid Tumor, HER2-negative Breast Cancer
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
- Trial name
- NCT06334432
- Testing
- NUV-1511
- Where
- 8 sites in United States
- Volunteers
- 466 people
- Sponsor
- Nuvation Bio Inc.
Advanced Solid Tumors
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
This is a Phase I/II, open-label, preliminary study of safety, tolerability, pharmacokinetics, and efficacy. The study comprises three parts: a Dose Escalation cohort, a Dose Expansion cohort, and an Efficacy Expansion cohort.
- Trial name
- NCT07253116
- Testing
- WJ22096
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Jingao biomidical technology Co. Ltd.
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers
This trial studies the delivery of the ENABLE palliative care program by two different methods called a Virtual Learning Collaborative or Technical Assistance for patients with advanced cancer and their caregivers.
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT04062552
- Testing
- Behavioral, Psychological or Informational Intervention, Educational Intervention, Medical Examination Assessment
- Where
- 113 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- University of Rochester NCORP Research Base
Advanced Solid Tumor, NSCLC
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
- Conditions
- Advanced Solid Tumor, NSCLC, CRC
- Trial name
- NCT05002270
- Testing
- JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor)
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Cancer, Lymphoma
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This is a Phase I/II, dose-escalation and expansion study of NUC-7738 administered by intravenous infusion as a monotherapy and in combination with pembrolizumab.
- Conditions
- Advanced Cancer, Lymphoma, Solid Tumor, Melanoma
- Trial name
- NCT03829254
- Testing
- NUC-7738, Pembrolizumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 135 people
- Sponsor
- NuCana plc